| Vol. 9.33 – 2 September, 2020 |
| |
|
|
| By using primary patient-derived medulloblastoma (MB) brain tumor-initiating cell lines, investigators characterized differences in the tumor-initiating capacity of Wnt, group three, and group four MB. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists used RNA-seq and clinical data of liver hepatocellular carcinoma from The Cancer Genome Atlas, Estimation of Stromal and Immune cells in Malignant Tumours, mRNA stemness index score, and weighted gene correlation network analysis methods to find genes significantly linked to the degree of immune infiltration and content of tumor stem cells. [Aging] |
|
|
|
| Tumor response to conventional bortezomib treatment was enhanced by targeted radiotherapy of resistant cancer stem cells that had characteristically poor proteasome function. [Scientific Reports] |
|
|
|
| Researchers found the existence of individual differences in the regional distribution of monocarboxylate transporters 1 and 4 and suggested that both transporters had distinct connections to glioblastoma multiforme progression processes. [International Journal of Molecular Sciences] |
|
|
|
| Scientists introduced lymph liquid biopsy through collection of peripheral and central lymph samples and demonstrated its feasibility for detection of stem‐like circulating tumor cells potentially responsible for metastasis development and tumor relapse. [Cytometry Part A] |
|
|
|
| Researchers revealed a novel function of Yes-associated protein 1 (YAP) and the mechanism underlying cancer stem cell regulation by YAP. [International Journal of Clinical Oncology] |
|
|
|
| Investigators identified an efficient, simple, and specific method of detecting mutations in the epidermal growth factor receptor gene in isolated lung cancer circulating tumor cells and to improve the ability to obtain tumor tissue clinically. [Thoracic Cancer] |
|
|
|
| Scientists established a CD133+ cell-rich subline from Capan-1 pancreatic cancer cells as a pancreatic cancer stem cell model and compared the effects of KU-0063794, a dual mTORC1/mTORC2 inhibitor, against those of mTORC1-specific rapamycin. [Human Cell] |
|
|
|
| Cellular uptake and localization assays demonstrated that decoy Oct4–Sox2 complex decoy oligodeoxynucleotides could efficiently be transfected to the cells and resided in the subcellular compartment, where they posed their action on gene regulation. [Molecular Biology Reports] |
|
|
|
|
| The authors discuss the causes and functional consequences of YAP dysregulation in head and neck squamous cell carcinoma (HNSCC). They also address interactions between YAP and other oncogenic drivers of HNSCC. [Experimental and Molecular Medicine] |
|
|
|
| Scientists revise the current knowledge of the molecular and genetic basis of the regulation by 1,25(OH)2D3 of the differentiation and stemness of human carcinoma cells, cancer-associated fibroblasts and cancer stem cells. [Cancers] |
|
|
|
| The authors illustrate the mechanism by which OCT4 plays a role in cancer stem cells from the perspective of genetic modification of OCT4, non-coding RNA, complexes and signaling pathways associated with OCT4. [International Journal of Stem Cells] |
|
|
|
|
| The FDA has approved Onureg® for the continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy and who was not able to complete intensive curative therapy. [Bristol Myers Squibb] |
|
|
|
|
|
|
|
| St. Anna Children’s Cancer Research Institute – Vienna, Austria |
|
|
|
| Sanford Burnham Prebys Medical Discovery Institute – La Jolla, California, United States |
|
|
|
| Northwestern University – Chicago, Illinois, United States |
|
|
|
| The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| Cincinnati Children’s Hospital Medical Center – Cincinnati, Ohio, United States |
|
|
|
|